Related references
Note: Only part of the references are listed.Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
Annamaria Ruzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Management of advanced colorectal cancer: state of the art
M. Saunders et al.
BRITISH JOURNAL OF CANCER (2006)
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy
Thierry Lecomte et al.
CLINICAL CANCER RESEARCH (2006)
Polymorphisms in genes of nucleotide and base excision repair:: Risk and prognosis of colorectal cancer
V Moreno et al.
CLINICAL CANCER RESEARCH (2006)
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer
J Viguier et al.
CLINICAL CANCER RESEARCH (2005)
Monitoring base excision repair by in vitro assays
GL Dianov
TOXICOLOGY (2003)
LDA - a java-based linkage disequilibrium analyzer
KY Ding et al.
BIOINFORMATICS (2003)
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer:: results of a multivariate analysis of 3825 patients
CH Köhne et al.
ANNALS OF ONCOLOGY (2002)
Share Paper
